Skip To Main Content
Brian Orelli on Muck Rack

Brian Orelli

San Diego
As seen in: BiotechTV, The Motley Fool (U.S.), MSN, Yahoo Finance, International Business Times (U.S.), Nasdaq, Thomson Reuters, Richmond Times-Dispatch, Billings Gazette, Greensboro News & Record, Roanoke Times, Bryan-College Station Eagle and
San Diego Contributing Corespondent for @BiotechTVHQ, Writer/analyst for @themotleyfool, @bioworld, and others
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Vaderis grabs $152M series B for HHT phase III

|
By Brian Orelli
| BioWorld Verified
Vaderis grabs $152M series B for HHT phase III Vaderis Therapeutics AG closed an oversubscribed $152 million series B to advance engasertib (VAD-044) as a treatment for hereditary hemorrhagic telangiectasia (HHT). The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital and existing investors, Medicxi and Droia. BioWorld Financings Series B Europe
Open in Who Shared Issue with article?

Tenax’s shares anything but ‘Level’ after failed phase III

|
By Brian Orelli
| BioWorld Verified
Tenax’s shares anything but ‘Level’ after failed phase III Tenax Therapeutics Inc. failed to show TNX-103 (oral levosimendan) improved the 6-minute walk distance endpoint compared to placebo in patients with pulmonary hypertension due to heart failure with preserved ejection fraction in the phase III Level study. BioWorld Clinical Cardiovascular Respiratory U.S.
Open in Who Shared Issue with article?

Expedition Therapeutics navigates $115M series B

|
By Brian Orelli
| BioWorld Verified
Expedition Therapeutics navigates $115M series B Expedition Therapeutics Inc. raised $115 million in a series B financing led by General Atlantic. RA Capital and Vivo Capital, as well as existing investors, Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners and Venrock Healthcare Capital Partners, also participated in the round. BioWorld Financings Respiratory Series B U.S.
Open in Who Shared Issue with article?
See all 992 licensed articles (2,797 Total)